(Q38796545)

6 September 2017

Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription (English)

1 reference

6 September 2017

1 reference

1 reference

1 reference

Pingjiang Ye

1

1 reference

6 September 2017

Haibo Xing

2

1 reference

6 September 2017

Fang Lou

3

1 reference

6 September 2017

Kaifeng Wang

4

1 reference

6 September 2017

Qin Pan

5

1 reference

6 September 2017

Xiaoyun Zhou

6

1 reference

6 September 2017

Liu Gong

7

1 reference

6 September 2017

Da Li

8

1 reference

6 September 2017

5 February 2016

1 reference

Cancer Chemotherapy and Pharmacology

6 September 2017

1 reference

6 September 2017

77

1 reference

6 September 2017

3

1 reference

6 September 2017

613-621

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-016-2979-9

6 September 2017

0 references

cites work

Current status of screening for colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Global cancer statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Long-term results and prognostic factors after resection of hepatic and pulmonary metastases of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Molecular mechanisms of multidrug resistance in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Histone deacetylase inhibitors and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Histone deacetylases and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Pharmacogenetics of membrane transporters: an update on current approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Decreased ABCB1 mRNA expression induced by atorvastatin results from enhanced mRNA degradation in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

FZD1 activates protein kinase C delta-mediated drug-resistance in multidrug-resistant MES-SA/Dx5 cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2979-9

10.1007/S00280-016-2979-9

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

0 references

1 reference